Abstract
OBJECTIVE: To evaluate whether Faricimab, which targets Ang-2, can reduce macular neovascularization (MNV) metrics on OCTA compared with Aflibercept in treatment-naïve nAMD. METHODS: Among 34 eyes treated with Aflibercept, 12 eyes were included; among 31 eyes treated with Faricimab, 14 eyes were included. Vessel area (Va) and junction density (JD) were measured using AngioTool over a 3-month loading period. RESULTS: In the Faricimab group, mean Va changed from 0.14 mm(2) at baseline to 0.15 mm(2) at 3 months; JD changed from 0.16 to 0.15/mm. In the Aflibercept group, Va decreased from 0.29 to 0.20 mm(2), and JD changed from 0.77 to 0.83/mm. Differences in Va and JD between groups were not statistically significant. CONCLUSION: There were no significant structural changes in MNV with either drug over the short term. These findings suggest that vascular effects of Faricimab may require longer observation to become evident.